menu
    • menu

    Company profile for Seneca Therapeutics

    NEW Drugs in Dev: 1
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Seneca Therapeutics was found by Dr. Paul Hallenbeck to develop the Seneca Valley Virus (“SVV-001”), a best in class oncolytic virus. SVV-001 is already in Phase I/II and has a clinical safety record in humans. SVV-001 binds to the TEM8 receptor which is common in many solid tumors like breast cancer, lung cancer and neuroendocrine tumors. SVV-001 is also being considered as a viral vector for gene therapy targeting the TE...
    Seneca Therapeutics was found by Dr. Paul Hallenbeck to develop the Seneca Valley Virus (“SVV-001”), a best in class oncolytic virus. SVV-001 is already in Phase I/II and has a clinical safety record in humans. SVV-001 binds to the TEM8 receptor which is common in many solid tumors like breast cancer, lung cancer and neuroendocrine tumors. SVV-001 is also being considered as a viral vector for gene therapy targeting the TEM8 receptor in solid tumors.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Seneca TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Blue Bell, Pa, 19422
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.senecatherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/seneca-therapeutics-inc/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Dr. Paul Hallenbeck to Present at Oncolytic Virotherapy Summit 2023
    Dr. Paul Hallenbeck to Present at Oncolytic Virotherapy Summit 2023

    11 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231211533367/en

    BUSINESSWIRE
    11 Dec 2023
    Share Share
    Dr. Paul Hallenbeck, CSO of Seneca to Present at World Vaccine Congress
    Dr. Paul Hallenbeck, CSO of Seneca to Present at World Vaccine Congress

    27 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231127359654/en

    BUSINESSWIRE
    27 Nov 2023
    Share Share
    Seneca Therapeutics Announces Publication of TEM8 Review Article
    Seneca Therapeutics Announces Publication of TEM8 Review Article

    15 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231115933889/en

    BUSINESSWIRE
    15 Nov 2023
    Share Share
    Seneca Therapeutics, Inc. Appoints Cuong Do to its Board of Directors
    Seneca Therapeutics, Inc. Appoints Cuong Do to its Board of Directors

    05 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230605005039/en

    BUSINESSWIRE
    05 Jun 2023
    Share Share
    Seneca Receives FDA Clearance to Begin SVV-001 Phase I/II Clinical Study
    Seneca Receives FDA Clearance to Begin SVV-001 Phase I/II Clinical Study

    03 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221003005089/en

    BUSINESSWIRE
    03 Oct 2022
    Share Share
    Industry Veteran Cuong Do Joins Seneca Therapeutics, Inc. Advisory Board
    Industry Veteran Cuong Do Joins Seneca Therapeutics, Inc. Advisory Board

    31 May 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220531005103/en

    BUSINESSWIRE
    31 May 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search